|Videos|April 19, 2023

Interview with LGM Pharma’s CEO, Prasad Raje

Author(s)LGM Pharma

Key Learning Objectives:

  • LGM Pharma reports strong revenues in its first year of CDMO operations and continued growth in its API Sourcing business
  • Offering API sourcing and CDMO services, plus Analytical Testing and new Drug Product R&D services, addresses the comprehensive needs of customers as LGM promotes its customer-centric strategies for growth.
  • LGM Pharma elevated its API sourcing network with the 2020 acquisition of NexGen Pharma’s CDMO business – enabling the one company to provide comprehensive services.


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.